Regeneron Pharmaceuticals Inc (REGN) PT Set at $447.00 by Piper Jaffray Cos.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has been given a $447.00 target price by Piper Jaffray Cos. in a research note issued on Thursday. The brokerage currently has a a “hold” rating on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s target price indicates a potential upside of 19.69% from the company’s current price.
REGN has been the subject of a number of other reports. Canaccord Genuity reaffirmed a “hold” rating and issued a $450.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, June 17th. Citigroup Inc. reaffirmed a “buy” rating and issued a $470.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 23rd. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a research report on Wednesday, June 29th. They issued an “outperform” rating and a $400.00 target price for the company. Vetr lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $419.76 target price for the company. in a research report on Monday, July 11th. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, July 11th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the company. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $480.09.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.08% during mid-day trading on Thursday, hitting $377.51. The stock had a trading volume of 379,784 shares. The firm’s 50-day moving average price is $399.99 and its 200-day moving average price is $392.12. Regeneron Pharmaceuticals has a 1-year low of $329.09 and a 1-year high of $592.59. The stock has a market cap of $39.50 billion, a PE ratio of 58.89 and a beta of 1.31.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/13/regeneron-pharmaceuticals-inc-regn-pt-set-at-447-00-by-piper-jaffray-cos.html
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.65 by $0.17. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The firm earned $1.21 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same period last year, the company posted $2.89 EPS. The business’s quarterly revenue was up 21.4% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals will post $11.02 earnings per share for the current year.
In related news, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction on Friday, July 29th. The stock was sold at an average price of $425.00, for a total value of $903,125.00. Following the transaction, the director now owns 15,125 shares of the company’s stock, valued at $6,428,125. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 10.40% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP boosted its position in shares of Regeneron Pharmaceuticals by 29.8% in the first quarter. Wellington Management Group LLP now owns 6,212,394 shares of the biopharmaceutical company’s stock worth $2,239,195,000 after buying an additional 1,426,801 shares during the period. Winslow Capital Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $291,760,000. FMR LLC boosted its position in shares of Regeneron Pharmaceuticals by 9.2% in the second quarter. FMR LLC now owns 9,416,836 shares of the biopharmaceutical company’s stock worth $3,288,642,000 after buying an additional 795,283 shares during the period. Norges Bank bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $387,661,000. Finally, Capital World Investors boosted its position in shares of Regeneron Pharmaceuticals by 4.4% in the second quarter. Capital World Investors now owns 7,326,626 shares of the biopharmaceutical company’s stock worth $2,558,678,000 after buying an additional 312,008 shares during the period. 68.16% of the stock is currently owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.